These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 31756301)
21. Initial treatment of CLL: integrating biology and functional status. Jain N; O'Brien S Blood; 2015 Jul; 126(4):463-70. PubMed ID: 26065656 [TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Patel KK; Isufi I; Kothari S; Davidoff AJ; Gross CP; Huntington SF Blood; 2020 Oct; 136(17):1946-1955. PubMed ID: 32518952 [TBL] [Abstract][Full Text] [Related]
23. SOHO State of the Art Updates and Next Questions: BTK inhibitors combined with chemoimmunotherapy in CLL, the best of both worlds? Thompson PA Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):205-209. PubMed ID: 34774461 [TBL] [Abstract][Full Text] [Related]
24. Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape. Iovino L; Shadman M Curr Treat Options Oncol; 2020 Mar; 21(4):24. PubMed ID: 32170458 [TBL] [Abstract][Full Text] [Related]
25. Relapsed CLL: sequencing, combinations, and novel agents. Brown JR Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):248-255. PubMed ID: 30504318 [TBL] [Abstract][Full Text] [Related]
26. Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Naïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis. Ronconi G; Dondi L; Calabria S; Piccinni C; Pedrini A; Esposito I; Martini N Clin Drug Investig; 2021 Jul; 41(7):595-604. PubMed ID: 34032988 [TBL] [Abstract][Full Text] [Related]
27. Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions. Cho HJ; Baek DW; Kim J; Lee JM; Moon JH; Sohn SK Expert Rev Hematol; 2021 Sep; 14(9):819-830. PubMed ID: 34375536 [TBL] [Abstract][Full Text] [Related]
28. Frontline Treatment of the Young, Fit Patient with CLL: A Canadian Perspective. Costello J; Kang M; Banerji V Curr Oncol; 2021 Sep; 28(5):3825-3835. PubMed ID: 34677244 [TBL] [Abstract][Full Text] [Related]
29. Prognostic markers and standard management of chronic lymphocytic leukemia. Stilgenbauer S Hematology Am Soc Hematol Educ Program; 2015; 2015():368-77. PubMed ID: 26637745 [TBL] [Abstract][Full Text] [Related]
30. The clinical safety of ibrutinib in chronic lymphocytic leukemia. Molica S Expert Opin Drug Saf; 2015 Oct; 14(10):1621-9. PubMed ID: 26359217 [TBL] [Abstract][Full Text] [Related]
32. Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial. Molica S Expert Rev Anticancer Ther; 2015 Jan; 15(1):9-15. PubMed ID: 25479582 [TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. Barnes JI; Divi V; Begaye A; Wong R; Coutre S; Owens DK; Goldhaber-Fiebert JD Blood Adv; 2018 Aug; 2(15):1946-1956. PubMed ID: 30097461 [TBL] [Abstract][Full Text] [Related]